好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Smartphone–Mediated, At-Home Telespirometry Vital Capacity (VC) Measurements in ALS: Point-of-Care Quality Assessment for Slow VC and Forced VC
General Neurology
P8 - Poster Session 8 (8:00 AM-9:00 AM)
2-006
Compare point-of-care (POC) quality assessment classifications of vital capacities measured with ZEPHYRx® Remote Respiratory Monitoring™ (RRM™) connected to the Breathe Easy application.
Smartphone application–mediated at-home telespirometry (AHT) aims to treat ALS-associated respiratory comorbidities. Forced vital capacity (FVC), previously manually evaluated, may now be assessed at POC by a software-based algorithm analyzing flow-volume-curve characteristics from American Thoracic Society/European Respiratory Society 2019 Spirometry Guidelines. 

Slow vital capacity (SVC) measurements are analyzed to achieve a plateau (volume change of ≤25 mL) in the last second of expiration. Expiratory time must be ≥15 seconds if a plateau is not reached.
Data sets (n=1538) representing the best erect SVC (eSVC) measurements in 98 subjects with ALS participating in a study of smartphone application–mediated, supervised AHT [NCT05106569] were compared with data sets (n=90) representing the best erect FVC (eFVC) measurements in 22 subjects with ALS participating in a pilot feasibility study of the ZEPHYRx Breathe Easy application combined with MIR Spirobank® Smart Spirometer and ZEPHYRx dashboard. POC SVC quality assessments generated by ZEPHYRx were compared with pilot study FVC quality assessments. POC eSVC (54.4%) were rated as grade A statistically significantly (P<0.0001) higher vs pilot study eFVC (18.8%). POC eSVC (40.8%) were rated as grade B-U statistically significantly (P<0.0001) lower vs eFVC (73.3%).
This is the first report evaluating software-assisted POC quality assessments of eSVC measurements compared with eFVC measurements using the ZEPHYRx RRM dashboard, MIR’s Spirobank Smart Spirometer, and Breathe Easy application. eSVC measurements met POC repeatability benchmarks at a higher level than eFVC measurements. Although the populations were different, the smartphone application, turbine spirometer, and respiratory therapy teams were comparable and POC repeatability was statistically significantly higher with eSVC measurements. This observation provides evidence that SVC may be the better measurement choice for patients with ALS.
Authors/Disclosures
George P. Slavinski, Respiratory Therapist (SUNY Upstate Medical University)
PRESENTER 		Mr. Slavinski has nothing to disclose.
Eufrosina I. Young, MD (Upstate University Hospital) The institution of Dr. Young has received research support from Mitsubishi Tanabe Pharma America.
Dongliang Wang Dongliang Wang has nothing to disclose.
Dragos Manta Dragos Manta has nothing to disclose.
Birendra Sah (Upstate Medical University) Birendra Sah has received publishing royalties from a publication relating to health care.
Urvi G. Desai, MD, FAAN (Dept of Neurology, CMC) Dr. Desai has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Desai has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fulcrum. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argenx.
Lena Deb (SUNY Upstate Medical University) Lena Deb has nothing to disclose.
Marielle Posmik Marielle Posmik has nothing to disclose.
Jeffrey P. Collins, RN Mr. Collins has nothing to disclose.
Emma Blystone, MS Ms. Blystone has nothing to disclose.
Jenny Meyer, MD (Upstate Medical University) The institution of Dr. Meyer has received research support from Grifols. The institution of Dr. Meyer has received research support from Medicinova.
Bhavya Narapureddy, MBBS (Upstate Medical University) Dr. Narapureddy has nothing to disclose.
Ahmed Ibrahim, MBBCH (Mayo Clinic) Dr. Ibrahim has nothing to disclose.
Grace Marie N. Dominguez, MD Dr. Dominguez has nothing to disclose.
Darshana Vijaywargiya, MBBS Dr. Vijaywargiya has nothing to disclose.
Sara Abdelhafiz, MBBS Dr. Abdelhafiz has nothing to disclose.
Pradeep Chevula, MD (17 Presidential Cts) Dr. Chevula has nothing to disclose.
Takuya Kudo (Mitsubishi Tanabe Pharma America, Inc.) Mr. Kudo has nothing to disclose.
Kinjal Patel Kinjal Patel has nothing to disclose.
Stephen Apple Stephen Apple has received personal compensation for serving as an employee of Mitsubishi Tanabe Pharma America, Inc.
Benjamin R. Brooks, MD, FAAN (Clinical Trials Planning LLC) Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medicinova. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma America. The institution of Dr. Brooks has received research support from Mitsubishi TanabePharma America. Dr. Brooks has received personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry. Dr. Brooks has a non-compensated relationship as a Member ALS Quality Measures Subcommittee with 好色先生 that is relevant to AAN interests or activities.